

## ASX Announcement

### Imugene appoints experienced life sciences CFO Mike Tonroe

---

**Sydney, Australia, 18 July 2022:** Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce the appointment of Mike Tonroe as Chief Financial Officer (CFO) who will commence in the newly created in house role, subject to finalisation of Mike's transition arrangements expected to be in early September 2022.

Mr Tonroe has extensive experience as a CFO and Company Secretary within the biopharmaceutical industry and also brings international finance leadership experience having worked in the US, Canada, UK and Hong Kong, in addition to Australia.

Most recently, Mr Tonroe was CFO and Company Secretary at ASX and NASDAQ-listed Genetic Technologies Limited and Opthea Limited, and prior to that was in the same role for private business Australian Synchrotron Company Ltd. These tenures included management of the US IPO and NASDAQ listing of Opthea along with M&A, restructuring, capital raising and leading the finance function across these businesses.

Adding to the depth of Mr Tonroe's experience, he has exposure to the technology, energy and travel sectors from earlier roles which also include time with major accounting firms KPMG and Deloitte.

Mr Tonroe graduated in Business Studies with Honours from Buckingham University UK, later becoming a Member then Fellow of the Institute of Chartered Accountants in England & Wales and being Australian Institute of Company Directors accredited.

Imugene's M.D. & CEO, Ms Leslie Chong said: "We've undertaken an extensive search recently to fill this important role within the business, with a view to finding someone that fits both in terms of expertise and the stage of the business, but also suits the culture at Imugene which we take great pride in. Mike is an outstanding appointment on these fronts and we are eager to see the positive impact his contribution will make to Imugene and the team."

For more information please contact:



**Leslie Chong**  
**Managing Director and Chief Executive Officer**  
info@imugene.com

**Investor Enquiries**  
investor@imugene.com

**Media Enquiries**  
Matt Wright  
matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene  
Like us on Facebook @Imugene  
Connect with us on LinkedIn @Imugene Limited  
View us on YouTube @Imugene Limited

### **About Imugene (ASX:IMU)**

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.



*Release authorised by the Managing Director and Chief Executive Officer  
Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia*